AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06349629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed WE43 magnesium alloy
Description: This 3D printed WE43 magnesium alloy has porous structure and suitable mechanical strength, can be stable in the bone support, and gradually degrade to promote bone healing.
Study NCT04925934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04561492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor
Description: Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor
Study NCT05316896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Perturbation
Description: * Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~* In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* Step forward and backward with right and left foot alternately~* Take a step back and step back alternately with right and left foot~* Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~* First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~* Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait.
Study NCT05316896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eksternal Perturbation
Description: * Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~* Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~* Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~* Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~* Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~* Holding the ball thrown by physiotherapist~* Kicking a ball thrown by physiotherapist~* Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards.
Study NCT05184738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Treatment, Oligomeric nutritional formula
Description: Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
Study NCT05184738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Treatment
Description: Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
Study NCT05976386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab (SAR231893)
Description: Injection solution Subcutaneous
Study NCT05976386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab (SAR231893)
Description: Injection solution Subcutaneous
Study NCT06609343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride 150 MG
Description: Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks
Study NCT05017480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection.
Study NCT05017480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous(SC) injection
Study NCT05217524 — intervention group
Intervention type: DEVICE
Intervention: Galaxy BIA watch
Description: Digital multifunction watch
Study NCT06118047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole Ointment
Description: Crisaborole ointment to be applied twice daily.
Study NCT06118047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab
Study NCT06487156 — intervention group
Intervention type: DRUG
Intervention: Nivolumab + ipilimumab
Description: As per product label
Study NCT05732207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial direct current stimulation
Description: TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
Study NCT05732207 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cerebellar transcranial direct current stimulation
Description: TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
Study NCT05046860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin.~In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment.~Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg.
Study NCT04915053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABG+ Black Garlin
Description: Daily tablet intake during three months
Study NCT04915053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystalline Cellulose
Description: Daily tablet intake during three months
Study NCT05601206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Description: Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
Study NCT05601206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Usual care from health providers
Study NCT04300348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heel2Toe
Description: Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
Study NCT04300348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-feedback control group
Description: The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
Study NCT05385601 — intervention group
Intervention type: OTHER
Intervention: eVOG (Mobile VideoOculoGraphy)
Description: * Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)
Study NCT05604430 — intervention group
Intervention type: DEVICE
Intervention: 731 Series Ventilator
Description: FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
Study NCT06333457 — intervention group
Intervention type: DEVICE
Intervention: VR Cue-Exposure Therapy
Description: Standard VR Cue Exposure Therapy (VR-CET) for the treatment of alcohol dependence
Study NCT06179992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGED mobile app
Description: The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
Study NCT06179992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGED mobile app
Description: The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
Study NCT05209347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
Study NCT06202794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Experimental group
Description: TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
Study NCT06202794 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control group
Description: Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
Study NCT05557747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervicothoracic junction mobilization in form of Maitland mobilization
Description: Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
Study NCT05557747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic muscle Energy Technique
Description: the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold
Study NCT05557747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
Study NCT05557747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
Study NCT05030363 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ALDH enzyme supplementation
Description: ALDH enzyme (PICOZYMEQ™)
Study NCT05030363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALDH enzyme supplementation
Description: ALDH enzyme (PICOZYMEQ™)
Study NCT05497921 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: handLITE LED device
Description: handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
Study NCT03965650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video coaching exercises
Description: Patients will perform physical exercises following a specifical video coaching program during 6 months.
Study NCT03965650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine exercises
Description: Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months.
Study NCT05227729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique
Description: While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
Study NCT06467175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling for high molecular weight DNA extraction
Description: 2 EDTA tubes will be taken for the index case, and the DNA will be extracted for sequencing into long-fragments and short-fragments. 1 EDTA tube will be taken for each relative.
Study NCT04681430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)
Study NCT04681430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Tablets over 7 days, daily dose of 600 mg split into 3 doses
Study NCT04681430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Camostat Mesilate
Description: Placebo Tablets over 7 days, split into 3 doses
Study NCT04681430 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: Control Arm for convalescent plasma (CP)
Study NCT06272019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine gargle
Description: Iodine gargle 0.2 %
Study NCT05838989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated Orthoses
Description: Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
Study NCT05838989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general and lumbrical muscle stretching
Description: Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
Study NCT05838989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
Study NCT05772988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: Beta-alanine
Study NCT05772988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study NCT05227729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique
Description: While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
Study NCT05026775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Medication Adherence (IMA)
Description: The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals.
Study NCT05026775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Health professionals in the usual care group will prescribe medication and provide information as usual.
Study NCT05038761 — intervention group
Intervention type: DEVICE
Intervention: CGM System
Description: Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days.
Study NCT05038761 — intervention group
Intervention type: PROCEDURE
Intervention: Standard Venous Blood Glucose Test
Description: Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
Study NCT05169671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1020
Description: ATH-1020 in oral capsule form
Study NCT05169671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in oral capsule form
Study NCT04507841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
Study NCT05428228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TP1
Description: Participants will be administered TP1 during one of the experimental visits.
Study NCT05428228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TP2
Description: Participants will be administered TP2 during one of the experimental visits.
Study NCT05428228 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo during one of the experimental visits.
Study NCT04906772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
Study NCT04906772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
Study NCT06606886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Metformin (Group A)
Description: Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
Study NCT06606886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Hydroxyurea (Group B)
Description: Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
Study NCT06612268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Etavopivat will be administered orally.
Study NCT06612268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Etavopivat will be administered orally.